Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab

Ustekinumab for the treatment of psoriasis is currently administered in a standard dosing regimen. However, some patients tend to benefit from alternative dosing regimens, a step toward personalized medicine. METHODS: To investigate the role of ustekinumab serum concentrations, anti-ustekinumab anti...

Descripción completa

Detalles Bibliográficos
Autores principales: De Keyser, Eline, Busard, Celine I., Lanssens, Sven, Meuleman, Lieve, Hutten, Barbara A., Costanzo, Antonio, van den Reek, Juul M., Zweegers, Jeffrey, Lambert, Jo, Spuls, Phyllis I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Therapeutic Drug Monitoring 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752798/
https://www.ncbi.nlm.nih.gov/pubmed/31107404
http://dx.doi.org/10.1097/FTD.0000000000000646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752798/
https://www.ncbi.nlm.nih.gov/pubmed/31107404
http://dx.doi.org/10.1097/FTD.0000000000000646

Ejemplares similares